Analysts Anticipate Horizon Pharma PLC (HZNP) to Announce $0.22 Earnings Per Share
Analysts predict that Horizon Pharma PLC (NASDAQ:HZNP) will report earnings per share (EPS) of $0.22 for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Horizon Pharma PLC’s earnings, with estimates ranging from $0.19 to $0.28. Horizon Pharma PLC posted earnings of $0.70 per share in the same quarter last year, which suggests a negative year over year growth rate of 68.6%. The business is expected to announce its next quarterly earnings results before the market opens on Monday, November 6th.
On average, analysts expect that Horizon Pharma PLC will report full year earnings of $1.04 per share for the current financial year, with EPS estimates ranging from $0.87 to $1.16. For the next fiscal year, analysts anticipate that the company will report earnings of $1.16 per share, with EPS estimates ranging from $0.95 to $1.33. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research analysts that cover Horizon Pharma PLC.
Horizon Pharma PLC (NASDAQ:HZNP) last posted its quarterly earnings data on Monday, August 7th. The biopharmaceutical company reported $0.41 EPS for the quarter, topping the consensus estimate of $0.12 by $0.29. Horizon Pharma PLC had a negative net margin of 42.40% and a positive return on equity of 22.85%. The business had revenue of $289.51 million for the quarter, compared to analyst estimates of $237.01 million. During the same quarter in the previous year, the firm posted $0.56 earnings per share. Horizon Pharma PLC’s quarterly revenue was up 12.5% on a year-over-year basis.
HZNP has been the topic of several recent research reports. ValuEngine cut shares of Horizon Pharma PLC from a “buy” rating to a “hold” rating in a report on Friday, September 1st. Cantor Fitzgerald set a $13.00 target price on shares of Horizon Pharma PLC and gave the stock a “buy” rating in a report on Monday, July 31st. Jefferies Group LLC reiterated a “buy” rating and set a $14.00 target price on shares of Horizon Pharma PLC in a report on Friday, July 14th. Piper Jaffray Companies set a $18.00 target price on shares of Horizon Pharma PLC and gave the stock a “buy” rating in a report on Sunday, September 10th. Finally, Zacks Investment Research upgraded shares of Horizon Pharma PLC from a “strong sell” rating to a “hold” rating in a report on Tuesday, July 11th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and eleven have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $18.00.
Shares of Horizon Pharma PLC (NASDAQ HZNP) opened at 13.86 on Tuesday. The company’s market cap is $2.26 billion. Horizon Pharma PLC has a 1-year low of $9.45 and a 1-year high of $21.98. The company’s 50-day moving average is $13.17 and its 200 day moving average is $12.66.
TRADEMARK VIOLATION WARNING: This news story was originally posted by American Banking News and is owned by of American Banking News. If you are reading this news story on another domain, it was illegally copied and republished in violation of U.S. & international trademark and copyright law. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2017/10/24/analysts-anticipate-horizon-pharma-plc-hznp-to-announce-0-22-earnings-per-share.html.
Several large investors have recently added to or reduced their stakes in the company. Ardsley Advisory Partners boosted its holdings in shares of Horizon Pharma PLC by 70.2% in the 2nd quarter. Ardsley Advisory Partners now owns 40,000 shares of the biopharmaceutical company’s stock valued at $475,000 after buying an additional 16,500 shares in the last quarter. Paulson & CO. Inc. bought a new stake in shares of Horizon Pharma PLC in the 2nd quarter valued at about $58,584,000. Family Management Corp bought a new stake in shares of Horizon Pharma PLC in the 2nd quarter valued at about $131,000. Proxima Capital Management LLC boosted its holdings in shares of Horizon Pharma PLC by 8.1% in the 2nd quarter. Proxima Capital Management LLC now owns 266,311 shares of the biopharmaceutical company’s stock valued at $3,161,000 after buying an additional 20,000 shares in the last quarter. Finally, The Manufacturers Life Insurance Company boosted its holdings in shares of Horizon Pharma PLC by 1.1% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 125,933 shares of the biopharmaceutical company’s stock valued at $1,495,000 after buying an additional 1,379 shares in the last quarter. Institutional investors and hedge funds own 82.32% of the company’s stock.
About Horizon Pharma PLC
Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Horizon Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.